Endpoints News May 28, 2026 #ASCO26: After leaving Legend, Frank Fan is ready to showcase his next project
Endpoints News May 28, 2026 Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy
Endpoints News May 28, 2026 China gene editing startup YolTech raises $70M to move CRISPR therapies forward
Endpoints News May 28, 2026 AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase
Endpoints News May 28, 2026 GSK spells out positive Phase 3 data for hepatitis B drug it licensed from Ionis
Endpoints News May 27, 2026 AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave
Endpoints News May 27, 2026 #ASCO26: Cancer immunotherapy's magic bullet era is fading. Here's what's next
Endpoints News May 26, 2026 Cartesian secures funding to 'accelerate' launch; Editas sells $125M in stock